Cargando…
Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region
BACKGROUND: Allergic rhinitis (AR) affects up to 36% of the population in the Middle East Gulf States. The second-generation nonsedating antihistamine desloratadine has demonstrated safety and efficacy in the treatment of AR; however, few studies have evaluated this agent in Arab and Asian populatio...
Autor principal: | Adham, Tamer MH |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651107/ https://www.ncbi.nlm.nih.gov/pubmed/23282541 http://dx.doi.org/10.1097/WOX.0b013e31822a6e9a |
Ejemplares similares
-
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]
por: Salmun, Luis M, et al.
Publicado: (2002) -
Desloratadine Therapy Improves Allergic Rhinitis Symptoms in Latin American Children Aged 6 to 12 Years
por: Tassinari, Paolo, et al.
Publicado: (2009) -
Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971].
por: Haye, Rolf, et al.
Publicado: (2005) -
Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial()
por: Wandalsen, Gustavo F., et al.
Publicado: (2016) -
247 Health-Related Quality of Life and Prognostic Value of Acoustic Rhinometry in Patients With Perennial Allergic Rhinitis Treated with Fix Combination of Montelukast Plus Desloratadine
por: Cingi, Cemal, et al.
Publicado: (2012)